Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Neural Transmission
Published in: Journal of Neural Transmission 7/2014

01-07-2014 | Neurology and Preclinical Neurological Studies - Short communication

IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®)

Authors: Dirk Dressler, Fereshte Adib Saberi, Hans Bigalke

Published in: Journal of Neural Transmission | Issue 7/2014

Login to get access

Abstract

IncobotulinumtoxinA has not produced a single case of antibody-induced therapy failure after 8 years of worldwide usage. We are reporting a patient with progressive hereditary juvenile onset generalised dystonia who was pretreated with abobotulinumtoxinA for 15 years, before she received incobotulinumtoxinA. To the fifth and sixth applications, she responded with complete therapy failure. Mouse hemidiaphragm assay testing revealed a maximal botulinum toxin antibody titre. Improved specific biological activity and lack of complexing proteins seem to reduce the antigenicity of incobotulinumtoxinA. However, this first ever report indicates that it does not eliminate it entirely.
Literature
Adib SF, Bigalke H, Dressler D (2010) Antigenicity differences between botulinum toxin drugs. Mov Disord 25(Suppl 2):S227 (Abstract)
Dressler D (2002) Clinical features of secondary failure of botulinum toxin therapy. Eur Neurol 48:26–29PubMedCrossRef
Dressler D (2012) Five-year experience with incobotulinumtoxinA (Xeomin®): the first botulinum toxin drug free of complexing proteins. Eur J Neurol 19:385–389PubMedCrossRef
Dressler D, Bigalke H (2009) Pharmacology of botulinum toxin drugs. In: Truong D, Dressler D, Hallett M (eds) Manual of botulinum toxin therapy. Cambridge University Press, Cambridge
Metadata
Title
IncobotulinumtoxinA (Xeomin®) can produce antibody-induced therapy failure in a patient pretreated with abobotulinumtoxinA (Dysport®)
Authors
Dirk Dressler
Fereshte Adib Saberi
Hans Bigalke
Publication date
01-07-2014
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 7/2014
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-014-1165-7

Other articles of this Issue 7/2014

Journal of Neural Transmission 7/2014 Go to the issue

Neurology and Preclinical Neurological Studies - Short communication

VPS35 Parkinson’s disease phenotype resembles the sporadic disease

Neurology and Preclinical Neurological Studies - Original Article

Deep brain stimulation of the amygdala alleviates fear conditioning-induced alterations in synaptic plasticity in the cortical–amygdala pathway and fear memory

Neurology and Preclinical Neurological Studies - Short communication

Coherence of coactivation and acceleration in task-specific primary bowing tremor

Translational Neurosciences - Original Article

Association of MDR1 gene C3435T polymorphism with childhood intractable epilepsy: a meta-analysis

Neurology and Preclinical Neurological Studies - Original Article

Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex

Neurology and Preclinical Neurological Studies - Original Article

Responsiveness to botulinum toxin type A in muscles of complex regional pain patients with tonic dystonia